Home > Insider Trading > Filing (0001209191-10-053401)

Filing Details

Accession Number:: 0001209191-10-053401
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2010-11-05 13:00:00
Reporting Period:: 2010-11-03

Filing Date:: 2010-11-05
Accepted Time:: 2010-11-05 16:02:53
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1326190	Pharmathene Inc	PIP	Pharmaceutical Preparations (2834)	202726770

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1173408	L.p. Iii Bioventures Mpm	C/O Mpm Asset Management 200 Clarendon St., 54Th Floor Boston MA 02116	No	No	Yes	No
1173409	L.p. Iii-Qp Bioventures Mpm	C/O Mpm Asset Management 200 Clarendon St., 54Th Floor Boston MA 02116	No	No	Yes	No
1249063	Mpm Bioventures Iii Parallel Fund, L.p.	C/O Mpm Asset Management 200 Clarendon St., 54Th Floor Boston MA 02116	No	No	Yes	No
1249133	Mpm Bioventures Iii Gmbh & Co. Beteiligungs Kg	C/O Mpm Asset Management 200 Clarendon St., 54Th Floor Boston MA 02116	No	No	Yes	No
1249143	L.p. Gp Iii Bioventures Mpm	C/O Mpm Asset Management 200 Clarendon St., 54Th Floor Boston MA 02116	No	No	Yes	No
1249147	Mpm Bioventures Iii Llc	C/O Mpm Asset Management 200 Clarendon St., 54Th Floor Boston MA 02116	No	No	Yes	No
1397371	Mpm Asset Management Investors 2004 Bviii Llc	C/O Mpm Asset Management 200 Clarendon St., 54Th Floor Boston MA 02116	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2010-11-03	2,428,171	$2.54	5,917,614	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2010-11-03	430,000	$3.50	6,347,614	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	10% Convertible Note	Disposition	2010-11-03	0	$0.00	2,428,171	$2.54

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2011-07-28	No	4	C	Indirect

Footnotes

These notes were held in principal amount as follows: $304,967.95 by MPM BioVentures III, L.P. ("BV III"), $4,535,272.77 by MPM BioVentures III-QP, L.P. ("BV III QP"), $383,274.43 by MPM BioVentures III GmbH & Co. Beteiligungs KG ("BV KG"), $136,981.07 by MPM BioVentures III Parallel Fund, L.P. ("BV Parallel") and $107,818.80 by MPM Asset Management Investors 2004 BVIII LLC ("AM 2004"). Amounts reflected above also include accrued interest on the notes as follows: $39,222.27 by BV III, $583,286.47 by BV III QP, $49,293.35 by BV KG, $17,617.29 by BV Parallel and $13,866.70 by AM 2004. MPM BioVentures III GP, L.P. ("MPM III GP") and MPM BioVentures III LLC ("MPM III LLC") are the direct and indirect general partners of BV III QP, BV III and BV Parallel and BV KG. Luke Evnin, Ansbert Gadicke, Nicholas Galakatos, Dennis Henner, Nicholas Simon III, Michael Steinmetz and Kurt Wheeler are the members of MPM III LLC and AM 2004. Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Immediately convertible into shares of Common Stock of the Issuer at the rate of $2.541667 per share.
The shares were acquired as follows: 135,419 by BV III, 2,013,859 by BV III QP, 170,191 by BV KG, 60,826 by BV Parallel and 47,876 by AM 2004.
The shares are held as follows: 330,024 by BV III, 4,907,913 by BV III QP, 414,765 by BV KG, 148,235 by BV Parallel and 116,677 by AM 2004. Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
The shares were purchased as follows: 23,981 by BV III, 356,630 by BV III QP, 30,139 by BV KG, 10,772 by BV Parallel and 8,478 by AM 2004.
The shares are held as follows: 354,005 by BV III, 5,264,543 by BV III QP, 444,904 by BV KG, 159,007 by BV Parallel and 125,155 by AM 2004. Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.